Impact of Hypsarrhythmia on Infantile Spasm Therapy

Infants experiencing spasms will likely respond to standard first-line treatment, whether or not they also have hypsarrhythmia, according to a multicenter study of the National Infantile Spasms Consortium.

• The investigation included infants between 2 months and 2 years who had been enrolled in the Consortium cohort with new onset spasms.
• 82% of the infants had hypsarrthythmia but the condition was not linked to the child’s average age, gender, any preexisting developmental delay or epilepsy, or their response to first line treatment.

First-line treatment, which consisted of vigabatrin, prednisolone, and adrenocorticotropic hormone (ACTH), was by far the most important variable that predicted the infants’ response to therapy, whether or not they had hypsarrhythmia.

The impact of hypsarrhythmia on infantile spasms treatment response: Observational cohort study from the National Infantile Spasms Consortium. Epilepsia. 2017;58:2098-2103.

Infants experiencing spasms will likely respond to standard first-line treatment, whether or not they also have hypsarrhythmia, according to a multicenter study of the National Infantile Spasms Consortium.

• The investigation included infants between 2 months and 2 years who had been enrolled in the Consortium cohort with new onset spasms.
• 82% of the infants had hypsarrthythmia but the condition was not linked to the child’s average age, gender, any preexisting developmental delay or epilepsy, or their response to first line treatment.

First-line treatment, which consisted of vigabatrin, prednisolone, and adrenocorticotropic hormone (ACTH), was by far the most important variable that predicted the infants’ response to therapy, whether or not they had hypsarrhythmia.

The impact of hypsarrhythmia on infantile spasms treatment response: Observational cohort study from the National Infantile Spasms Consortium. Epilepsia. 2017;58:2098-2103.

Infants experiencing spasms will likely respond to standard first-line treatment, whether or not they also have hypsarrhythmia, according to a multicenter study of the National Infantile Spasms Consortium.

• The investigation included infants between 2 months and 2 years who had been enrolled in the Consortium cohort with new onset spasms.
• 82% of the infants had hypsarrthythmia but the condition was not linked to the child’s average age, gender, any preexisting developmental delay or epilepsy, or their response to first line treatment.

First-line treatment, which consisted of vigabatrin, prednisolone, and adrenocorticotropic hormone (ACTH), was by far the most important variable that predicted the infants’ response to therapy, whether or not they had hypsarrhythmia.

The impact of hypsarrhythmia on infantile spasms treatment response: Observational cohort study from the National Infantile Spasms Consortium. Epilepsia. 2017;58:2098-2103.